慢性丙型肝炎治疗:优化与发展

Treatment for chronic hepatitis C:optimization and development

聚乙二醇干扰素α联合利巴韦林已成为慢性丙型肝炎的标准治疗方法,但仍有部分患者未能获得持续病毒学应答(sustained virologic response,SVR)。根据治疗基线时的病毒载量、基因型以及治疗过程中的应答可以优化抗病毒治疗的方案。对于标准治疗或延长疗程仍不能获得SVR者,通过特异性靶向抗丙型肝炎病毒治疗可以提高应答。对于其他的难治性丙型肝炎患者,包括合并HIV感染者、肝硬化患者以及器官移植患者,抗病毒治疗也取得了进展。

Pegylated interferon α and ribavirin combination treatment has been a standard treatment for chronic hepatitis C, however, some patients fail to achieve sustained virologic response （SVR）. According to viral load, genotype and on-treatment response at baseline, antiviral therapy regimens can be optimized. Specific targeted antiviral therapy for hepatitis C is effective for some difficult-to-treat patients, who fail to achieve SVR by standard treatment or extended treatment duration. Progress has also been made in the antiviral therapy of other difficult-to-treat patients, such as HCV/HIV co-infected patients, cirrhotic patients and transplanted patients, etc.